Januvia

Sitagliptin, the active ingredient in Januvia, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral administration. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used in combination with diet and exercise.

GNH USA supplies Januvia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance and regulatory compliance for global distribution. We provide reliable logistics, batch traceability and support for import documentation.

Januvia (sitagliptin) belongs to the DPP‑4 inhibitor class used to manage type 2 diabetes mellitus. It works within the glucose‑regulation pathway to improve glycaemic control. - Type 2 diabetes mellitus: improves blood glucose levels as part of a comprehensive treatment plan that includes diet and exercise.

Sitagliptin may cause adverse reactions; the following side effects have been reported.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient head pain of varying intensity. - Upper respiratory tract infection: symptoms such as cough and sore throat. - Nausea: feeling of stomach upset or urge to vomit. - Diarrhoea: loose, frequent stools.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: including angioedema or anaphylaxis. - Joint pain: unexplained arthralgia that may be disabling. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes. - Hepatic enzyme elevations: rare liver function abnormalities.

When prescribing or dispensing sitagliptin, consider the following precautions. - Assess renal function: dose adjustment may be required in patients with impaired renal function. - Monitor for signs of pancreatitis: discontinue if pancreatitis is suspected. - Avoid in patients with known hypersensitivity to sitagliptin or any excipients. - Use caution with concomitant insulin or sulfonylureas: increased risk of hypoglycaemia. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Sitagliptin can interact with other medicines; notable interactions include:

Major Interactions (Avoid): - Insulin or sulfonylureas: may increase risk of hypoglycaemia. - Rifampin: may reduce sitagliptin plasma concentrations, decreasing efficacy. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure.

Moderate Interactions (Monitor Closely): - ACE inhibitors: possible increased risk of angioedema. - Diuretics: may affect glucose control; monitor blood sugar. - Warfarin: may require INR monitoring due to potential interaction.